How TheraB Medical is Transforming Maternal & Infant Health

Innovative wearable technology for babies with jaundice

Neonatal jaundice affects 60-80% of newborns worldwide

Neonatal jaundice is a significant global health concern, affecting millions of newborns annually. This condition, caused by elevated bilirubin levels in the blood, results in yellowing of the skin and eyes. High levels of bilirubin, untreated, may lead to seizures, deafness, cerebral palsy, and mental retardation. Approximately 60% of full-term and 80% of preterm infants experience jaundice in their first week of life.

Traditional treatment disrupts the early bonding experience

The traditional treatment for jaundice involves placing infants under phototherapy lights. The duration of their treatment varies but can range from a few hours to many hours a day over several days. While life-saving, this treatment disrupts the early bonding experience between mother and infant.

Early bonding and quality time between mother and baby are fundamental in shaping the child's and mother's long-term well-being and resilience. Early bonding, including skin-to-skin contact and nursing, creates a strong foundation for the child's overall development and supports the mother's mental and emotional health. Given the critical importance of this time together, it's clear that treatment for jaundice is long overdue for an upgrade.

TheraB Medical’s Solution

TheraB Medical is a medical technology company dedicated to developing innovative solutions for infant care. Focusing on neonatology and early infant health, they create products that improve patient outcomes and simplify clinical workflows for healthcare professionals.

Their premiere product, the SnugLit, is a patented, wearable phototherapy device designed to treat newborn jaundice while allowing parents to hold and bond with their infants. Developed with input from over 300 doctors, nurses, and parents, SnugLit represents a paradigm shift in managing neonatal jaundice.

Unlike traditional methods that require infants to lie beneath stationary lights, SnugLit’s portable design enables continuous, effective treatment without compromising the essential mother-infant bond. Its innovative design delivers the necessary blue light therapy to break down bilirubin molecules while allowing for continuous bonding and breastfeeding. The SnugLit Portable Phototherapy Blanket also offers a seamless transition from hospital to home, ensuring consistent care and comfort for newborns. 

By bringing innovative solutions like SnugLit to neonatal care, TheraB Medical ensures that the smallest patients receive the best possible start in life. Through continuous improvement and dedication to infant health, TheraB Medical is transforming how jaundice is treated, positively impacting the lives of newborns and their families.

For more information about TheraB, visit and follow them on LinkedIn.

For more information on Femovate, visit and follow us on LinkedIn.

For interviews, please contact Theresa Neil.

Stay in touch

The application period for Femovate 2023-24 is now closed. Follow us on LinkedIn for updates and the selected startups announcement.